M. Cecilia Bahit on Muck Rack

M. Cecilia Bahit

Verified
Rosario
As seen in: CardiologyNowNews, Medscape, Wiley Online Library, heart, The Lancet, AHA/ASA Journals, JACC (Journal of the American College of Cardiology), International Journal of Cardiology
❤️ MD. Researcher. Certified English Translator. Medical Writer.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with M. Cecilia

Contact M. Cecilia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Prevention of heart failure after acute myocardial infarction

|
By Jacob A. Udell, M. Cecilia Bahit Verified, INECO Neurociencias Oroño, Fundación INECO
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Dwyer, Jr, EM ∙ Greenberg, H ∙ Case, RB Association between transient pulmonary congestion during acute myocardial infarction and high incidence of death in six months Am J Cardiol. 1986; 58:900-905 2. Butler, J ∙ Hammonds, K ∙ Talha, KM ∙ et al. Incident heart failure and recurrent coronary events following acute myocardial infarction Eur Heart J. 2025; 46:1540-1550 3. Khan, SS ∙ Fiuzat, OBM ∙ McMurray, JJV ∙ et al.
Open in Who Shared Issue with article?

Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels:

|
By Sem A.O.F. Rikken, C. Michael Gibson, M. Cecilia Bahit Verified, Danielle Duffy
| JACC (Journal of the American College of Cardiology)
Introduction Despite modern guideline-directed medical therapy, patients who survive an acute myocardial infarction (AMI) remain at high risk for recurrent cardiovascular events, particularly in the first 90 days following the index event.1-3 Recurrent events link to persistent thrombin generation, residual inflammation, and elevated low-density lipoprotein cholesterol (LDL-C) levels, which together contribute to atherosclerotic plaque instability, thrombosis, and myocardial damage.4,5...
Open in Who Shared Issue with article?

Effect of CSL112 on Recurrent Myocardial Infarction and Cardiovascular Death: Insights from the AEGIS-II Trial:

|
By Thomas J. Povsic, M.D. Ph.D, Serge Korjian, M. Cecilia Bahit Verified
| JACC (Journal of the American College of Cardiology)
ABSTRACT Background The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction (MI) among high-risk patients with MI. Objectives This exploratory analysis evaluates the effect of CSL112 therapy on the incidence of CV death and recurrent MI.
Open in Who Shared Issue with article?
See all 12 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified